Evidence map›Paper›PMID 39259509›Full record

ArticleImmunotherapy2024

Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review.

Lei Liu, Tengfei Long, Nannan Wei, Hongyan Zhang, Chaoliang Tang, Jin Gao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lei LiuDepartment of Radiotherapy and Oncology, Hefei Ion Medical Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230088, China.ORCID 0000-0003-4493-1678
Tengfei LongDepartment of Radiotherapy and Oncology, Hefei Ion Medical Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230088, China.
Nannan WeiDepartment of Radiotherapy and Oncology, Hefei Ion Medical Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230088, China.
Hongyan ZhangDepartment of Radiotherapy and Oncology, Hefei Ion Medical Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230088, China.
Chaoliang TangDepartment of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Jin GaoDepartment of Radiotherapy and Oncology, Hefei Ion Medical Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230088, China.

Funding

Anhui Provincial Department of Education Scientific Research Project Grant No. 2022AH020076 to Chaoliang TangAnhui Provincial Natural Science Foundation Grant No. 2208085Y32 to Chaoliang TangChen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province Grant No. CXPJJH12000005-07-115 to Chaoliang TangHefei Municipal Natural Science Foundation project Grant No.202333 to Jin Gao
6 · The paper itself

Abstract

Trichilemmal carcinoma (TC) is a rare, malignant cutaneous adnexal tumor. TC often has nonspecific clinical manifestations and its aggressive nature is frequently overlooked. Metastasis of TC is rarely reported and there is no standard treatment for recurrent or metastatic TC. We report a complicated case of TC arising from the parotid gland with metastasis to cervical lymph nodes. The tumor progressed after multiple surgeries, radiation and chemotherapy. Finally, the patient achieved good response and disease control with pembrolizumab, an immune checkpoint inhibitor targeting programmed cell death protein-1. Currently, the patient has received 19 cycles of pembrolizumab and the disease remains well controlled. This represents the first reported use of immune checkpoint blockade to treat TC.

Indexed as

Antibodies, Monoclonal, HumanizedLymphatic MetastasisSkin NeoplasmsAntineoplastic Agents, ImmunologicalHumansImmune Checkpoint InhibitorsNeoplasm MetastasisParotid NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitorspembrolizumabcutaneous oncologyPD-1/PD-L1 checkpoint blockadepembrolizumabtrichilemmal carcinoma

Identifiers

PMID39259509
PMCPMC11404700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.